Aethlon Medical, Inc. (OTC:AEMD) bounced up the 50-day moving average yesterday on intensive trading activity. The company seems on the right track with its therapy under development, yet nothing is certain yet. 
AEMD opened the market yesterday with a gap up and then closed the session exactly at the 50-day moving average at $0.06. That means a 13.21% jump up from the previous close, but in general the share price remains within the established trading range. Trading volume reached 1.37 million traded shares for the day.
50- and 200-day moving averages are going down currently, which confirms that AEMD is following a downtrend in the last six months. That is not a surprise, looking at the last reported financial condition of the company. At the end of last September, AEMD had a striking working capital deficit of over $6 million with only $46,000 in cash and no considerable tangible assets.
AEMD reports also no revenues whatsoever for the three quarters ending September 2011, and the announcement from yesterday could not change the general state of the company any time soon. It concerned the company’s blood filtration therapy which has demonstrated immediate virologic responses in infected HCV patients during the tests.
Also, last September the company was engaged by the Defense Advanced Research Project Agency (DARPA) to develop a therapeutic device that reduces the incidence of sepsis and upon the reaching of certain milestones AEMD could receive payments for a total of $6.79 million. A first payment has already been received, yet the company still has to find additional new capital rapidly in order to sustain its operations.
